Biotron Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BITRF research report →
Price Chart
About the company
Biotron Limited is an Australian biotechnology firm focused on the development and market introduction of small-molecule compounds designed to combat various viral infections. The company's primary antiviral agent, BIT225, is currently undergoing Phase II clinical trials to assess its efficacy against SARS-CoV-2, HIV-1, and hepatitis C virus infections. Founded in 1999, Biotron Limited's main offices are situated in Sydney, Australia.
- CEO
- Michelle Miller GCertAppFin
- IPO
- 2013
- Employees
- 3
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on BITRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.18M
- P/E
- -2.22
- PEG
- 0.00
- P/S
- -3785.25
- P/B
- 1.11
- EV/EBITDA
- -0.85
- Div Yield
- 0.00%
- Gross Margin
- 190.21%
- Op Margin
- 222203.69%
- Net Margin
- 223061.06%
- ROE
- -119.12%
- ROIC
- -71.46%
Latest fiscal year · YoY change
- Revenue
- $1.81M+10.2%
- Gross Profit
- $1.81M+13.0%
- Op Income
- $-338,751
- Net Income
- $-318,572+90.7%
- EPS
- $-0.00+92.1%
- OCF Growth
- +84.1%
- FCF Growth
- +84.1%
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- -0.64
- RSI (14)
- 26
- Avg Volume
- 10.48K
No earnings-call transcripts are available for BITRF yet.
- Free Float
- 108.5%
- Shares Outstanding
- 906.81M
- Float Shares
- 983.52M
Our BITRF coverage
Recent articles, reports, and earnings notes.
No research on BITRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BITRF report →